Chimerix Ebola Drug OK’d; Tekmira Drops On Downgrade
Ebola-related stocks continued to be volatile on the stock market today as Chimerix received an emergency authorization for its experimental drug, while Tekmira Pharmaceuticals plunged after a downgrade. Chimerix’s (CMRX) Brincidofovir, an oral antiviral drug, is in late-stage testing for a different problem, cytomegalovirus infection in blood-cancer patients who receive stem-cell transplants. However, test-tube experiments in government labs